EOM Pharmaceutical Holdings (filed under ImmunoCellular Therapeutics), which is developing in-licensed therapies for inflammatory and ocular diseases, filed on Friday with the SEC to raise up to $25 million in an initial public offering. The company is currently listed on the OTC Pink under the ticker "IMUC".
The company is developing therapies for inflammatory conditions and ocular diseases. EOM Pharmaceutical's portfolio currently consists of two candidates: EOM613, which was acquired from Neubase Therapeutics (formerly OHR Pharmaceutical) in May 2020, and EOM147, a formulation of OHR Pharmaceutical's OHR-102 ophthalmic solution formulation. The company is currently in the process of initiating IND-enabling studies of EOM613 that would enable it to proceed into new Phase 2 trials of cancer cachexia and rheumatoid arthritis by the 1Q23. It also anticipates evaluating EOM147 in a Phase 2b trial in chronic retinal disease patients in the 1Q23.
The Montvale, NJ-based company was founded in 2020 and plans to list on the Nasdaq under the symbol EOM. EOM Pharmaceutical Holdings filed confidentially on February 10, 2022. EF Hutton is the sole bookrunner on the deal. No pricing terms were disclosed.
